恩杂鲁胺联合雄激素剥夺治疗用于异时性转移性激素敏感性前列腺癌的总生存分析
基于ENZAMET试验中期分析,312例初诊为M0后发生异时性转移的激素敏感性前列腺癌患者中,加用恩杂鲁胺后总生存风险比(HR)为0.56(95%CI 0.29-1.06),低瘤负荷亚组HR为0.40(95%CI 0.16-0.97),3年OS在全体患者中为83%对89%,低瘤负荷亚组为83%对92%。
要点
- 异时性转移患者加用恩杂鲁胺后HR(OS)为0.56(95%CI 0.29-1.06)。
- 低瘤负荷亚组HR(OS)为0.40(95%CI 0.16-0.97),获益更明显。
- 低瘤负荷亚组3年OS:无恩杂鲁胺83%,加用恩杂鲁胺92%。
核心结论
- 对于初诊M0、后发生异时性转移的激素敏感性前列腺癌患者,加用恩杂鲁胺可改善总生存,低瘤负荷亚组获益显著。
研究设计与样本
- ENZAMET试验中期分析,前瞻性纳入初诊分类为M0的异时性转移性激素敏感性前列腺癌患者,幸存者中位随访34个月。
- 1125例入组患者中312例(28%)初诊为M0,其中205例(66%)在研究入组时按CHAARTED标准为低瘤负荷。
主要发现
- 全体异时性转移患者加用恩杂鲁胺的HR(OS)为0.56(95%CI 0.29-1.06)。
- 低瘤负荷亚组加用恩杂鲁胺的HR(OS)为0.40(95%CI 0.16-0.97)。
- 全体患者3年OS:无恩杂鲁胺83%,加用恩杂鲁胺89%。
- 低瘤负荷亚组3年OS:无恩杂鲁胺83%,加用恩杂鲁胺92%。
关键数值与推荐
- 低瘤负荷按CHAARTED标准判定,312例中205例(66%)符合。
- 全体异时性转移患者HR(OS) 0.56(95%CI 0.29-1.06),低瘤负荷亚组HR(OS) 0.40(95%CI 0.16-0.97)。
- 全体患者3年OS 83%对89%,低瘤负荷亚组3年OS 83%对92%。
临床怎么用
- 对异时性转移性激素敏感性前列腺癌患者,应强烈考虑在睾酮抑制基础上加用恩杂鲁胺等强化内分泌治疗。
- 低瘤负荷异时性转移患者从强化内分泌治疗中获益更显著,决策时应结合瘤负荷评估。
局限性
- 本文为ENZAMET试验中期分析,幸存者中位随访34个月,总生存数据尚不成熟。
- 全体患者HR(OS)的95%CI上限跨越1.0,统计显著性未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Men who initially present with localized prostate cancer and later develop metachronous metastases have a better prognosis than men with de novo metastatic disease and often have a low burden of disease on conventional imaging. Some have disease amenable to metastasis-directed therapy for lymph node or bone metastases, a strategy used by some because no documented overall survival (OS) benefit of combination systemic therapy in this setting. We report data for patients prospectively classified as "M0" at initial diagnosis from the interim analysis of the ENZAMET trial, with 34 mo of median follow-up for survivors. A total of 312 (28%) of the 1125 enrolled patients were classified as M0 at diagnosis, and 205 (66%) of the 312 patients had low-volume disease at study entry as per the CHAARTED criteria. The hazard ratio for OS, that is, HR(OS), was 0.56 (95% confidence interval [CI]: 0.29-1.06) with the addition of enzalutamide for all patients with metachronous metastatic hormone-sensitive prostate cancer, and for the low-volume subset the HR(OS) was 0.40 (95% CI: 0.16-0.97). The 3-yr OS was 83% without and 89% with enzalutamide for all patients with metachronous metastases, and 83% and 92%, respectively, for the low-volume subset. Intensification of hormonal therapy should strongly be considered for these men. PATIENT SUMMARY: Many men present with prostate cancer that has spread to distant sites beyond the prostate gland years after their initial diagnosis and treatment, while others have distant spread at the time the cancer is diagnosed. On average, men whose cancer comes back years after the initial diagnosis often survive much longer than men whose cancer has been found to spread to distant sites when it is first diagnosed. In this report, we demonstrate strong evidence for the first time that the survival of men whose cancer comes back years later is improved when drugs such as enzalutamide or apalutamide are added to testosterone suppression in this setting.
引用
- Sweeney CJ, Martin AJ, Stockler MR, et al. Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. Eur Urol. 2021. PMID: 34030924. doi:10.1016/j.eururo.2021.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。